Evotec stock: EUR 2.98, up 0.34% premarket
Published on 11/16/2026 at 07:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec's business and market position
- Evotec combines technology, drug research and artificial intelligence with partnerships to advance medicines.
- Just - Evotec Biologics is positioned as a growth catalyst, while the pipeline is intended to generate milestones and licensing revenue.
Evotec stock gains before Xetra trading
Evotec stock traded at EUR 2.98 on Lang & Schwarz at 07:56 CET on Monday, November 16, 2026, 0.34 percent above the Xetra close of Friday, November 13, 2026.
Evotec develops medicines through technology-led drug research, artificial intelligence and partnerships. The company describes Just - Evotec Biologics as a key growth catalyst and highlights milestone and licensing revenue from its pipeline. Further details are available from Evotec investor relations.
German equities remain the relevant market backdrop for investors following the stock; see current market reports.
Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70519563 | bgmi
